Itonic (NASDAQ:ITOC – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.09) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $0.23 million for the quarter.
Itonic Trading Up 4.4%
Shares of Itonic stock opened at $0.41 on Tuesday. Itonic has a 12-month low of $0.25 and a 12-month high of $32.00.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings assumed coverage on shares of Itonic in a research note on Tuesday, February 10th. They issued a “sell (e+)” rating on the stock. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.
Itonic Company Profile
iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients.
Featured Stories
Receive News & Ratings for Itonic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Itonic and related companies with MarketBeat.com's FREE daily email newsletter.
